Hypertrophic cardiomyopathy is an inherited myocardial disorder characterized by unexplained left ventricular hypertrophy and variable clinical manifestations ranging from asymptomatic disease to heart failure, arrhythmia, or sudden cardiac death. It is commonly caused by pathogenic variants in sarcomeric protein genes. Clinical management is risk-stratified and long-term.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07361289 |
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China |
RECRUITING | |
| NCT07103057 |
VIZ ACCESS HCM - Multi-Site Registry |
RECRUITING | |
| NCT07033455 |
A Trial of HRS-1893 in Healthy Volunteers |
COMPLETED | EARLY_PHASE1 |
| NCT07021963 |
A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy |
RECRUITING | PHASE2 |
| NCT06873828 |
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring |
NOT_YET_RECRUITING | PHASE3 |
| NCT06775886 |
Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy |
TERMINATED | NA |
| NCT06775834 |
Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function |
COMPLETED | PHASE1 |
| NCT06610019 |
Cardiovascular Multimodality Imaging Study |
RECRUITING | |
| NCT06600256 |
Viz HCM (ECG Assist) Utilization Workflow Pilot |
COMPLETED | |
| NCT06573723 |
Institutional Registry of Rare Diseases |
RECRUITING |
